Verastem, Inc. Presents Updated Clinical Data From VS-6063 And Paclitaxel Combination Phase 1/1b Study In Patients With Ovarian Cancer At The 2014 American Society of Clinical Oncology Annual Meeting

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of clinical data in a poster presentation and discussion at the American Society of Clinical Oncology Annual Meeting being held May 30 – June 3, 2014, at McCormick Place in Chicago, IL.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC